PUBLISHER: Lucintel | PRODUCT CODE: 1417528
PUBLISHER: Lucintel | PRODUCT CODE: 1417528
Asthma and COPD Drugs Trends and Forecast
The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets. The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030 with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.
A more than 150-page report is developed to help in your business decisions.
Asthma and COPD Drugs by Segment
The study includes a forecast for the global asthma and COPD drugs by diseases, medication class, and region.
List of Asthma and COPD Drugs Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies asthma and COPD drugs companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the asthma and COPD drugs companies profiled in this report include-
Asthma and COPD Drugs Market Insights
Lucintel forecasts that combination drug will remain the largest segment over the forecast period.
North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.
Features of the Global Asthma and COPD Drugs Market
Market Size Estimates: Asthma and COPD drugs market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Asthma and COPD drugs market size by diseases, medication class, and region in terms of value ($B).
Regional Analysis: Asthma and COPD drugs market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different diseases, medication class, and regions for the asthma and COPD drugs market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the asthma and COPD drugs market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the asthma and COPD drugs market size?
Answer: The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030.
Q2. What is the growth forecast for asthma and COPD drugs market?
Answer: The global asthma and COPD drugs market is expected to grow with a CAGR of 4.3% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the asthma and COPD drugs market?
Answer: The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.
Q4. What are the major segments for asthma and COPD drugs market?
Answer: The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets.
Q5. Who are the key asthma and COPD drugs market companies?
Answer: Some of the key asthma and COPD drugs companies are as follows.
Q6. Which asthma and COPD drugs market segment will be the largest in future?
Answer: Lucintel forecasts that combination drug will remain the largest segment over the forecast period.
Q7. In asthma and COPD drugs market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.